E-submission
THE KOREAN LIVER CANCER ASSOCIATION
Search
- Page Path
- HOME > Search
Original Article
- Effect of direct-acting antivirals for hepatitis C virus-related hepatocellular carcinoma recurrence and death after curative treatment
- Young-Hwan Ahn, Heirim Lee, Ji Eun Han, Hyo Jung Cho, Jae Youn Cheong, Bumhee Park, Soon Sun Kim
- J Liver Cancer. 2022;22(2):125-135. Published online June 28, 2022
- DOI: https://doi.org/10.17998/jlc.2022.05.24
- 2,990 Views
- 78 Downloads
- 4 Citations
-
Abstract
PDF
Supplementary Material - Background/Aim
There has been a long-standing debate about the association of directacting antiviral (DAA) therapy and hepatocellular carcinoma (HCC) recurrence. This study aimed to investigate the association between DAA therapy and HCC recurrence after curative therapy.
Methods
We retrospectively enrolled 1,021 patients with HCV-related (hepatitis C virus) HCC who underwent radiofrequency ablation (RFA), liver resection, or both as the first treatment modality from January 2007 to December 2016 and without a history of HCV therapy before HCC treatment from a nationwide database. The effect of HCV treatment on HCC recurrence and all-cause mortality was also investigated.
Results
Among the 1,021 patients, 77 (7.5%) were treated with DAA, 14 (1.4%) were treated with interferon-based therapy, and 930 (91.1%) did not receive HCV therapy. DAA therapy was an independent prognostic factor for lower HCC recurrence rate (hazard ratio [HR], 0.04; 95% confidence interval [CI], 0.006-0.289; P=0.001 for landmarks at 6 months after HCC treatment and HR, 0.05; 95% CI, 0.007-0.354; P=0.003 for landmarks at 1 year). Furthermore, DAA therapy was associated with lower all-cause mortality (HR, 0.049; 95% CI, 0.007-0.349; P=0.003 for landmarks at 6 months and HR, 0.063; 95% CI, 0.009-0.451; P=0.006 for landmarks at 1 year).
Conclusions
DAA therapy after curative HCC treatment can decrease HCC recurrence and all-cause mortality compared to interferon-based therapy or no antiviral therapy. Therefore, clinicians should consider administering DAA therapy after curative HCC treatment in patients with HCV-related HCC. -
Citations
Citations to this article as recorded by
- Comparison of Surgical Resection and Radiofrequency Ablation in Elderly Patients with Hepatocellular Carcinoma
Jun Il Kim, Jayoun Lee, Gi Hong Choi, Min Woo Lee, Dong Ah Park, Jeong-Ju Yoo
Digestive Diseases and Sciences.2024; 69(3): 1055. CrossRef - Analyzing risk factors and developing a stratification system for hepatocellular carcinoma recurrence after interferon-free direct-acting antiviral therapy in chronic hepatitis C patients
Chih-Hsuan Luan, Pin-Shuo Su, Chi-Jen Chu, Chung-Chi Lin, Chien-Wei Su, Jiing-Chyuan Luo, I-Cheng Lee, Chen-Ta Chi, Shou-Dong Lee, Yuan-Jen Wang, Fa-Yauh Lee, Yi-Hsiang Huang, Ming-Chih Hou
Journal of the Chinese Medical Association.2024; 87(4): 357. CrossRef - Addition of Kidney Dysfunction Type to MELD-Na for the Prediction of Survival in Cirrhotic Patients Awaiting Liver Transplantation in Comparison with MELD 3.0 with Albumin
Kyeong-Min Yeom, Jong-In Chang, Jeong-Ju Yoo, Ji Eun Moon, Dong Hyun Sinn, Young Seok Kim, Sang Gyune Kim
Diagnostics.2023; 14(1): 39. CrossRef - Is direct-acting antiviral treatment beneficial or harmful for patients with hepatitis C virus-related hepatocellular carcinoma?
Hye Won Lee
Journal of Liver Cancer.2022; 22(2): 91. CrossRef
- Comparison of Surgical Resection and Radiofrequency Ablation in Elderly Patients with Hepatocellular Carcinoma
Case Report
- A Case of Successful Treatment for Recurrent Hepatocellular Carcinoma with Long term Survival
- Jin Hyoung Lee, Ja Kyung Kim, Hwa Sook Kim, Sang Hoon Ahn, Chae Yoon Chon, Young Myoung Moon, Kwang-Hyub Han, Woo Jung Lee, Young Nyun Park, Seung Hyoung Kim, Kwang Hoon Lee, Do Yun Lee, Jong Tae Lee
- Journal of the Korean Liver Cancer Study Group. 2006;6(1):20-24. Published online June 30, 2006
- 495 Views
- 0 Download
-
Abstract
PDF
- The long term results of surgery for hepatocelluar carcinoma are not satisfactory, because the high incidence of intrahepatic tumor recurrence, with a 5-year acturial recurrence rate of 75% to 100%. The risk factors for postoperative recurrence such as venous invasion, presence of satellite nodules, large tumor size, advanced TNM stages are the best-established. For the management of postoperative recurrence, studies largely focused on the recurrence in the remnant liver. The therapeutic modalities commonly used for surgical resection, TACE, percutaneous ethanol injection (PEIT), and systemic chemotherapy. We report a case of recurrent hepatocellular carcinoma after curative resection, successfully treated by TACE, TACI, and systemic chemotherapy with long term survival.
First
Prev
Follow JLC on Twitter